Trump Orders Marijuana Reclassification, Acknowledging Past Critiques

President Donald Trump has issued an executive order to reclassify marijuana from Schedule I to Schedule III of the Controlled Substances Act. This significant shift, announced last week, aligns with longstanding critiques regarding the classification of marijuana, which has been deemed one of the most dangerous drugs despite evidence supporting its medical use.

Schedule I drugs, which include substances like heroin and LSD, are said to have a high potential for abuse and no accepted medical use. However, Francis Young, a former chief administrative law judge at the Drug Enforcement Administration (DEA), asserted in 1988 that marijuana did not belong in this category. Although his findings were ultimately dismissed by then-DEA Administrator John Lawn, Trump’s recent order implicitly acknowledges Young’s long-standing argument that the federal government has mischaracterized marijuana’s potential benefits.

Under the new classification, marijuana will join substances like ketamine and anabolic steroids in Schedule III, which are recognized for having accepted medical applications. This move comes after a comprehensive review by the Department of Health and Human Services (HHS), initiated by President Joe Biden, which found credible scientific support for marijuana’s medical use in treating conditions such as pain, nausea, and anorexia.

The HHS report concluded that marijuana does not warrant placement in Schedule I or II, stating, “While marijuana is associated with a high prevalence of abuse, the profile of and propensity for serious outcomes related to that abuse lead to a conclusion that marijuana is most appropriately controlled in Schedule III.” Attorney General Merrick Garland endorsed this recommendation in May 2024, and Trump has expressed urgency in finalizing the proposed rule.

While this reclassification is a step towards recognizing marijuana’s medical benefits, it does not legalize its use. Medical applications will still require approval from the Food and Drug Administration (FDA), and state-licensed marijuana businesses will continue to operate in a legal gray area under federal law. Nevertheless, rescheduling marijuana will ease some regulatory burdens, facilitating medical research and allowing businesses to claim standard tax deductions, which could significantly lower their effective tax rates.

Since Young’s initial ruling, 40 states have legalized marijuana for medical purposes, with 24 of those states also permitting recreational use. This widespread acceptance has created a notable conflict with federal prohibition, a stance that polls show many Americans oppose. Trump emphasized that his order “doesn’t legalize marijuana in any way, shape or form,” a statement that some may find disappointing given the current landscape of public opinion and state legislation.

The executive order represents a pivotal moment in the ongoing debate over marijuana’s legal status. It not only highlights the evolving understanding of the substance but also raises questions about the future of drug policy in the United States, as the nation grapples with the implications of federal versus state laws concerning marijuana.